141 related articles for article (PubMed ID: 25955428)
21. Comparative evaluation of T11 target structure and its deglycosylated derivative nullifies the importance of glycan moieties in immunotherapeutic efficacy.
Chatterjee S; Acharya S; Kumar P; Chatterjee A; Chaudhuri S; Ghosh A; Chaudhuri S
Acta Biochim Biophys Sin (Shanghai); 2012 Mar; 44(3):259-68. PubMed ID: 22257732
[TBL] [Abstract][Full Text] [Related]
22. Immunizations with unmodified tumor cells and simultaneous COX-2 inhibition eradicate malignant rat brain tumors and induce a long-lasting CD8(+) T cell memory.
Eberstål S; Fritzell S; Sandén E; Visse E; Darabi A; Siesjö P
J Neuroimmunol; 2014 Sep; 274(1-2):161-7. PubMed ID: 25022336
[TBL] [Abstract][Full Text] [Related]
23. Sheep form of leucocyte function antigen-3 (T11TS) exerts immunostimulatory and anti-tumor activity against experimental brain tumor. A new approach to biological response modifier therapy.
Sarkar S; Begum Z; Dutta S; Dutta SK; Chaudhuri S; Chaudhuri S
J Exp Clin Cancer Res; 2002 Mar; 21(1):95-106. PubMed ID: 12071536
[TBL] [Abstract][Full Text] [Related]
24. Effects of gamma-interferon on major histocompatibility complex antigen expression and lymphocytic infiltration in the 9L gliosarcoma brain tumor model: implications for strategies of immunotherapy.
Wen PY; Lampson MA; Lampson LA
J Neuroimmunol; 1992 Jan; 36(1):57-68. PubMed ID: 1735769
[TBL] [Abstract][Full Text] [Related]
25. Treatment of intracranial glioma with in situ interferon-gamma and tumor necrosis factor-alpha gene transfer.
Ehtesham M; Samoto K; Kabos P; Acosta FL; Gutierrez MA; Black KL; Yu JS
Cancer Gene Ther; 2002 Nov; 9(11):925-34. PubMed ID: 12386831
[TBL] [Abstract][Full Text] [Related]
26. Documentation of immune profile of microglia through cell surface marker study in glioma model primed by a novel cell surface glycopeptide T11TS/SLFA-3.
Begum Z; Ghosh A; Sarkar S; Mukherjee J; Mazumdar M; Sarkar P; Chaudhuri S
Glycoconj J; 2004; 20(9):515-23. PubMed ID: 15454689
[TBL] [Abstract][Full Text] [Related]
27. Interleukin-23-expressing bone marrow-derived neural stem-like cells exhibit antitumor activity against intracranial glioma.
Yuan X; Hu J; Belladonna ML; Black KL; Yu JS
Cancer Res; 2006 Mar; 66(5):2630-8. PubMed ID: 16510582
[TBL] [Abstract][Full Text] [Related]
28. Cellular immunity in the treatment of brain tumors.
Wheeler CJ; Yu JS; Black KL
Clin Neurosurg; 2004; 51():132-9. PubMed ID: 15571138
[No Abstract] [Full Text] [Related]
29. Antitumor activity against established intracerebral gliomas exhibited by cytotoxic T lymphocytes, but not by lymphokine-activated killer cells.
Holladay FP; Heitz T; Wood GW
J Neurosurg; 1992 Nov; 77(5):757-62. PubMed ID: 1403119
[TBL] [Abstract][Full Text] [Related]
30. Antitumor effect of immunizations with fusions of dendritic and glioma cells in a mouse brain tumor model.
Akasaki Y; Kikuchi T; Homma S; Abe T; Kofe D; Ohno T
J Immunother; 2001; 24(2):106-13. PubMed ID: 11265767
[TBL] [Abstract][Full Text] [Related]
31. Synergism between GM-CSF and IFNgamma: enhanced immunotherapy in mice with glioma.
Smith KE; Janelidze S; Visse E; Badn W; Salford L; Siesjö P; Darabi A
Int J Cancer; 2007 Jan; 120(1):75-80. PubMed ID: 17044023
[TBL] [Abstract][Full Text] [Related]
32. Cure of established GL261 mouse gliomas after combined immunotherapy with GM-CSF and IFNgamma is mediated by both CD8+ and CD4+ T-cells.
Smith KE; Fritzell S; Badn W; Eberstål S; Janelidze S; Visse E; Darabi A; Siesjö P
Int J Cancer; 2009 Feb; 124(3):630-7. PubMed ID: 18972433
[TBL] [Abstract][Full Text] [Related]
33. Intratumorally implanted mesenchymal stromal cells potentiate peripheral immunotherapy against malignant rat gliomas.
Ströjby S; Eberstål S; Svensson A; Fritzell S; Bexell D; Siesjö P; Darabi A; Bengzon J
J Neuroimmunol; 2014 Sep; 274(1-2):240-3. PubMed ID: 25086876
[TBL] [Abstract][Full Text] [Related]
34. Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model.
Ali S; King GD; Curtin JF; Candolfi M; Xiong W; Liu C; Puntel M; Cheng Q; Prieto J; Ribas A; Kupiec-Weglinski J; van Rooijen N; Lassmann H; Lowenstein PR; Castro MG
Cancer Res; 2005 Aug; 65(16):7194-204. PubMed ID: 16103070
[TBL] [Abstract][Full Text] [Related]
35. Principles of immunotherapy.
Liebelt BD; Finocchiaro G; Heimberger AB
Handb Clin Neurol; 2016; 134():163-81. PubMed ID: 26948354
[TBL] [Abstract][Full Text] [Related]
36. Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens.
Liau LM; Black KL; Prins RM; Sykes SN; DiPatre PL; Cloughesy TF; Becker DP; Bronstein JM
J Neurosurg; 1999 Jun; 90(6):1115-24. PubMed ID: 10350260
[TBL] [Abstract][Full Text] [Related]
37. The innate immune response in the central nervous system and its role in glioma immune surveillance.
Friese MA; Steinle A; Weller M
Onkologie; 2004 Oct; 27(5):487-91. PubMed ID: 15585981
[TBL] [Abstract][Full Text] [Related]
38. [Immunomodulatory effects of interferons on target human gliosarcoma cells in the tumor-specific CTL- and LAK-mediated cytolysis].
Miyatake S; Kondou S; Aoki T; Iwasaki K; Ohyama K; Ootsuka S; Oda Y; Kikuchi H
No Shinkei Geka; 1991 Nov; 19(11):1053-9. PubMed ID: 1762655
[TBL] [Abstract][Full Text] [Related]
39. Immune stimulatory effects of CD70 override CD70-mediated immune cell apoptosis in rodent glioma models and confer long-lasting antiglioma immunity in vivo.
Aulwurm S; Wischhusen J; Friese M; Borst J; Weller M
Int J Cancer; 2006 Apr; 118(7):1728-35. PubMed ID: 16217761
[TBL] [Abstract][Full Text] [Related]
40. Aspects of immunobiology and immunotherapy and uses of monoclonal antibodies and biologic immune modifiers in human gliomas.
Lee Y; Bigner DD
Neurol Clin; 1985 Nov; 3(4):901-17. PubMed ID: 2417097
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
